98%
921
2 minutes
20
Within the last two decades, no studies have comprehensively reviewed the risk of varying types of ultraviolet (UV) exposure on melanoma in fairer skinned individuals. Our research objective was to determine whether or not there was a change in the risk of UV exposure with development of melanoma in Fitzpatrick skin types I-IV based on more recent data over the past 20 years. We performed a systematic review from January 2002 to December 2021 analysing UV exposure and melanoma risk in Fitzpatrick type I-IV individuals. Out of 19,852 studies, 26 met inclusion criteria. Data spanned subjects from national and multinational cohorts (USA, Europe, Australia, Asia and South America). Twenty studies (77%, 20/26) identified a significant association between UV exposure and melanoma incidence. Sunburn was the most commonly assessed risk factor. Sunburn studies encompassed 3417 melanoma and found positive significant odds ratios (OR [95% CI]) in 11 out of 13 studies, ranging from 1.23 [1.01-1.49] to 8.48 [4.35-16.54]. Pooled analysis of the risk of melanoma with sunburn history found an unadjusted odds ratio of 1.66 [1.40-1.97] and adjusted odds ratio of 1.23 [1.04-1.46]. Cumulative sun exposure, measured as number of hours of sun exposure or calculated UV flux, was the second most common risk factor, encompassing 913 melanomas with positive significant ORs ranging from 1.1 [1.0-1.2] to 5.2 [2.1-12.5]. For other forms of UV exposure, a majority of studies showed an association with UV index (6/9), outdoor leisure activity (3/3) and left-sided laterality (1/1). Overall, UV exposure should continue to be considered a modifiable risk factor for melanoma in individuals of fairer skin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jdv.20316 | DOI Listing |
Indian J Dermatol
September 2025
From the Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Background: Several studies have reported the association between statin use and skin cancer; however, the results have been conflicting. Furthermore, no large-scale studies have reported the relationship between statin exposure and skin cancer in Asian countries.
Aims: The aim of this study was to investigate the association between statin exposure and skin cancer in Korea.
J Public Health (Oxf)
September 2025
Benchmark Risk Group, 121 West Wacker Dr., Suite 2800 Chicago, IL 60601, USA.
Background: There is a demand for population level research on the potential genetic-basis of mesothelioma (e.g. BRCA1-associated protein-1 [BAP1]) independent of other risk factors, such as amphibole asbestos exposure.
View Article and Find Full Text PDFAdv Healthc Mater
September 2025
Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794, USA.
Compared to sun-exposed melanomas, acral melanomas are genetically diverse and occur in areas with low sun exposure and high mechanical loads. During metastatic growth, melanomas invade from the epidermis to the dermis layers through dense tumor stroma and are exposed to fibrillar collagen architectures and mechanical stresses. However, the role of these signals during acral melanoma pathogenesis is not well understood.
View Article and Find Full Text PDFJ Clin Pharmacol
September 2025
Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, CA, USA.
Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T-VEC) is a first-in-class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T-VEC that supported the development of this unique therapy.
View Article and Find Full Text PDFBackground: Patients with BRAF wild type (wt) metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICI) face a poor prognosis. Chemotherapy has been shown to induce genetic mutations, modify the tumor microenvironment and microbiome, and influence immune system activity.
Objectives: This prospective multicenter phase II trial investigates whether two applications of an alkylating agent (dacarbazine/DTIC) can sensitize ICI non-responsive patients with metastatic melanoma to the same checkpoint inhibitor regime.